Notable Adverse Events from TRuE-V Studies

EP: 1.TRuE-V Studies Overview and Unmet Needs in Vitiligo

EP: 2.Safety and Efficacy Data Results at 24-Week Mark of TRuE-V Studies

EP: 3.TRuE-V Long-Term Extension Study Design

EP: 4.Key Results from the TRuE-V Long-term Extension Study

Now Viewing

EP: 5.Notable Adverse Events from TRuE-V Studies

EP: 6.Evaluating TRuE-V Study Limitations

EP: 7.Payer Considerations Surrounding TRuE-V Studies

In this segment of the discussion on vitiligo, Gary Owens, M.D., and David Rosmarin, M.D.,delve into the adverse events associated with the long-term use of the drug ruxolitinib. They emphasize the importance of considering both efficacy and safety in drug evaluation. Notably, they highlight that there have been no new side effects observed in the long-term extension of the study that were not previously seen in the initial phase. They discuss the similarities in infection results between patients initially using ruxolitinib cream and those switched from a vehicle to the medication. The experts express their views that the reported adverse events are likely random occurrences, not directly related to the treatment. They specifically mention the common occurrences of application site acne and pruritus. Overall, the discussion underscores the safety profile of the drug, emphasizing its topical nature and limited impact on the body surface area.

Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.